News from Karo Pharma

6 May, 2021

Karo Pharma to sell its treasury shares

Karo Pharma (“Karo”) pursues a growth strategy, which combines geographical expansion with an active acquisition strategy. To execute on this strategy, Karo needs capital and a strong financial position. The treasury shares represent an unutilized resource in the company and a sale of the shares enhances Karo’s financial flexibility. On October 30, 2020 Karo communicated...

28 April, 2021

Karo Pharma resolves on sale of own shares

Under the the authorization from the 2021 Annual General Meeting, the Board of Directors has resolved to sell up to 1,768,000 own shares to expand the company’s financial flexibility. The sale of own shares shall be effected – on one or several occasions before the 2022 Annual General Meeting, where a new mandate should be...

1 April, 2021

Karo Pharma completes the acquisition of the brand portfolio from Teva Pharmaceuticals

Karo Pharma Aktiebolag (“Karo”) today announces that the acquisition of the European OTC brand portfolio from Teva Pharmaceuticals (Teva) for 84 MEUR, which was signed and announced on 3 February 2021, has been completed. The transaction transfers ownership of the brand portfolio, comprised of Flux ®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva to...

3 February, 2021

Karo Pharma acquires European OTC brand portfolio from Teva Pharmaceuticals

Karo Pharma Aktiebolag (“Karo”) today announces the acquisition of an OTC brand portfolio containing Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva Pharmaceuticals (Teva) for a total consideration of EUR 84m.